Prexton Therapeutics
About Prexton Therapeutics
Prexton Therapeutics is a company founded in 2012 was acquired by Lundbeck in March 2018.. Prexton Therapeutics has raised $43.46 million across 3 funding rounds from investors including Lundbeck, Forbion and Seroba Lifesciences. Prexton Therapeutics operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Prexton Therapeutics
Prexton Therapeutics has successfully raised a total of $43.46M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $31 million completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $31.0M
-
First Round
First Round
(30 Jul 2012)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2017 | Amount | Series B - Prexton Therapeutics | Valuation |
investors |
|
| Feb, 2015 | Amount | Series A - Prexton Therapeutics | Valuation |
investors |
|
| Jul, 2012 | Amount | Seed - Prexton Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Prexton Therapeutics
Prexton Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Lundbeck, Forbion and Seroba Lifesciences. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on lifescience and healthcare sectors
|
Founded Year | Domain | Location | |
|
Ysios Capital is recognized as a leading life sciences investor.
|
Founded Year | Domain | Location | |
|
Investments are made by Sunstone in early-stage European companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Prexton Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Prexton Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Prexton Therapeutics Comparisons
Competitors of Prexton Therapeutics
Prexton Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Biologics platform developed for intracellular delivery in rare diseases.
|
|
| domain | founded_year | HQ Location |
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
|
|
| domain | founded_year | HQ Location |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Prexton Therapeutics
Frequently Asked Questions about Prexton Therapeutics
When was Prexton Therapeutics founded?
Prexton Therapeutics was founded in 2012.
Is Prexton Therapeutics a funded company?
Prexton Therapeutics is a funded company, having raised a total of $43.46M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2.59M, raised on Jul 30, 2012.
What does Prexton Therapeutics do?
Prexton Therapeutics was founded in 2012 and operates in the biotechnology sector, focusing on treatments for Parkinsons disease. Metabotropic glutamate receptors mGluR3 and mGluR4 are targeted through the development of positive allosteric modulators to enhance mGluR4 activity. These receptors interact with glutamate, an excitatory neurotransmitter linked to functions such as learning, memory, anxiety, and pain perception. Motor behaviors in Parkinsons patients are expected to be restored by this approach.
Who are the top competitors of Prexton Therapeutics?
Prexton Therapeutics's top competitors include Alector, Intra-Cellular Therapies and Entrada Therapeutics.
Who are Prexton Therapeutics's investors?
Prexton Therapeutics has 6 investors. Key investors include Lundbeck, Forbion, Seroba Lifesciences, Ysios Capital, and Sunstone.